Aeglea Biotherapeutics

OverviewSuggest Edit

Aeglea BioTherapeutics is a biotherapeutic company exploiting the amino acid (AA) dependencies of many tumors by developing novel, human-derived AA-degrading enzymes which have been engineered to have optimized catalytic and biopharmaceutic properties. The metabolic basis of tumor amino acid dependence is fundamentally different from the nutritional needs of normal tissues, creating a vulnerability to selective killing of tumor cells. Aeglea’s first two programs utilize enzymes that degrade either the amino acid L-methionine (Met) or L-arginine (Arg) for use as therapy in oncology. The Company's therapeutic strategy takes advantage of decades of clinical validation to leverage the genetic and epigenetic basis of tumor AA auxotrophy to identify patients likely to benefit from these molecules.
TypePublic
Founded2013
HQAustin, US
Websiteaegleabio.com

Latest Updates

Employees (est.) (Dec 2018)61(+9%)
Share Price (Oct 2019)$7.8 (-1%)

Key People/Management at Aeglea Biotherapeutics

M.B Anthony Quinn

M.B Anthony Quinn

President & Chief Executive Officer
James Wooldridge

James Wooldridge

Chief Medical Officer
Charles N. York

Charles N. York

CFO
Aaron Schuchart

Aaron Schuchart

Chief Business Officer
Scott W. Rowlinson

Scott W. Rowlinson

Vice President of Research
Leslie Sloan

Leslie Sloan

COO
Show more

Aeglea Biotherapeutics Office Locations

Aeglea Biotherapeutics has an office in Austin
Austin, US (HQ)
Barton Oaks Plaza One, 901 S MoPac Expy #250
Show all (1)

Aeglea Biotherapeutics Financials and Metrics

Aeglea Biotherapeutics Revenue

USD

Net income (FY, 2018)

(44.3m)

EBIT (FY, 2018)

(45.5m)

Market capitalization (18-Oct-2019)

225.9m

Closing stock price (18-Oct-2019)

7.8

Cash (31-Dec-2018)

22.5m
Aeglea Biotherapeutics's current market capitalization is $225.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

8.4m10.1m12.6m

R&D expense

18.1m22.8m36.7m

Operating expense total

26.5m32.9m49.4m

EBIT

(21.9m)(27.7m)(45.5m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

General and administrative expense

1.8m2.4m2.1m2.4m2.4m2.9m5.8m

R&D expense

3.6m4.4m5.4m4.9m5.8m6.9m16.0m

Operating expense total

5.4m6.9m7.5m7.3m8.2m9.8m21.8m

EBIT

(4.6m)(5.5m)(6.3m)(6.3m)(6.7m)(8.2m)(17.9m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

47.7m12.8m22.5m

Accounts Receivable

164.2m

Inventories

1.7m

Current Assets

66.4m55.0m76.7m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

24.0m70.6m49.5m16.8m26.9m10.8m20.6m

Current Assets

35.2m76.9m71.7m60.3m66.2m48.8m78.9m

PP&E

321.0k377.0k342.0k822.0k802.0k810.0k776.0k

Total Assets

35.5m77.3m72.1m61.3m67.1m49.8m79.7m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(21.7m)(27.2m)(44.3m)

Depreciation and Amortization

132.0k249.0k293.0k

Inventories

(96.1k)

Accounts Payable

(8.0k)164.0k239.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(4.5m)(10.0m)(16.2m)(6.2m)(8.1m)(17.5m)

Depreciation and Amortization

29.0k62.0k96.0k52.0k70.0k145.0k

Accounts Payable

261.0k172.0k347.0k95.0k396.0k579.0k

Cash From Operating Activities

(4.0m)(8.6m)(14.5m)(5.4m)(7.4m)(16.5m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics

Aeglea Biotherapeutics Operating Metrics

FY, 2016

Nonclinical Development

3

Phase Approved

1

Phase I Trials Products

2

Phase I/II Trials Products

1
Show all operating metrics

Aeglea Biotherapeutics Online and Social Media Presence

Embed Graph

Aeglea Biotherapeutics News and Updates

Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights

FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences

AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D., presid…

Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights

Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design

Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences

AUSTIN, Texas, March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that Anthony G. Quinn, M.B. Ch.B, …

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights

On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019
Show more

Aeglea Biotherapeutics Blogs

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency Content Import Wed, 07/24/2019 - 16:07 Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficien…

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency Content Import Mon, 06/03/2019 - 08:53 Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency 06…

Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders

Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders Content Import Mon, 04/01/2019 - 08:09 Aeglea BioTherapeutics to Present Up…

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency Content Import Tue, 12/11/2018 - 16:07 Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency …

Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference

Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference Content Import Thu, 12/06/2018 - 16:08 Aeglea BioTherapeutics to Present at BMO Capital Markets 2018 Prescription for Success Healthcare Conference 12/06/18 …

Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Content Import Thu, 11/08/2018 - 08:06 Aeglea BioTherapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights 11/08/18 This release…
Show more

Aeglea Biotherapeutics Frequently Asked Questions

  • When was Aeglea Biotherapeutics founded?

    Aeglea Biotherapeutics was founded in 2013.

  • Who are Aeglea Biotherapeutics key executives?

    Aeglea Biotherapeutics's key executives are M.B Anthony Quinn, James Wooldridge and Charles N. York.

  • How many employees does Aeglea Biotherapeutics have?

    Aeglea Biotherapeutics has 61 employees.

  • Who are Aeglea Biotherapeutics competitors?

    Competitors of Aeglea Biotherapeutics include Aptevo Therapeutics, Cleveland BioLabs and Immune Design.

  • Where is Aeglea Biotherapeutics headquarters?

    Aeglea Biotherapeutics headquarters is located at Barton Oaks Plaza One, 901 S MoPac Expy #250, Austin.

  • Where are Aeglea Biotherapeutics offices?

    Aeglea Biotherapeutics has an office in Austin.

  • How many offices does Aeglea Biotherapeutics have?

    Aeglea Biotherapeutics has 1 office.